Eliot Forster

Eliot Forster is a seasoned biotechnology executive with a robust background in leadership and innovation within the industry. Currently serving as Chief Executive Officer at Levicept Ltd, Eliot is spearheading the development of LEVI-04 for chronic pain management, which is in a phase II clinical trial. Eliot holds non-executive roles at Tessellate BIO and Immatics, and previously chaired the board at AVACTA GROUP PLC. With a track record that includes CEO positions at F-star Therapeutics and Immunocore, alongside significant leadership at Creabilis SA and Oxford BioTherapeutics, Eliot combines a PhD in Neurophysiology from the University of Liverpool with an MBA from Henley Business School.